key: cord-0862382-tz162pwn
authors: Chen, Jiezhong; Vitetta, Luis
title: Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19
date: 2021-09-30
journal: Clin Immunol
DOI: 10.1016/j.clim.2021.108870
sha: 8c9de69acfa7e482f4f09956c3d2a1b5656137aa
doc_id: 862382
cord_uid: tz162pwn

nan

Hyperinflammation plays a central role in the pathogenesis of severe COVID-19 and thus anti-hyperinflammation is a key for the treatment of severe COVID-19 to reduce mortality [1] . The report by Corominas and colleagues demonstrated that the anti-IL6 receptor antibody tocilizumab (TCZ) importantly and significantly reduced the mortality rate of those patients diagnosed with moderate or severe COVID-19 compared with hospitalized patients' mortality rate [2] . Cytokines collaborate with other key features of COVID-19 such as direct viral infections and microvascular thrombosis to progress multi-organ failure [1] . Given that ACE2 is expressed in many cell types, SARS-CoV-2 may infect multiple organs. The grave vascular thrombosis may also block the blood supply to an organ, that as such then triggers severe consequences. In addition, the cytokine storm could be associated with lymphopenia, another characteristic of severe COVID-19, causing decreased clearance of the virus. A study reported that the combination of increased IL-6 levels and decreased CD8 + T-cell frequency was a reliable predictor for COVID-19 caused mortality [3] . Although IL-6 is a major cytokine, many other proinflammatory cytokines are involved in hyperinflammation of severe COVID-19. Therefore, there is an opportunity to further inhibit hyperinflammation that reduces mortality with severe COVID-19. We posit that commensal bacterial metabolites could be an effective option to be combined with TCZ.

Many chronic diseases have been identified as risk factors such as lung disease, heart disease, hypertension, obesity, diabetes and kidney disease [1] . The effects expounded by these chronic diseases could be accounted for by widespread chronic and systemic inflammation. [1] . Butyrate, an anti-inflammatory short-chain fatty acid, has been extensively studied. In a healthy gut microbiota, butyrate is produced in millimolar levels [4] .

It exerts anti-inflammatory effects through multiple mechanisms [1] . Butyrate can activate anti-inflammatory immune cells such as regulatory T cells and M2 macrophages. It also inhibits inflammatory signalling pathways through histone deacetylase-dependent and independent manners. Furthermore, butyrate has anti-viral and anti-bacterial effects. Butyrate can increase mucin secretion to decrease the contact of pathobionts with intestinal cells and enhance the production of defensins, which have direct effect on viruses [5] . In a rat gut epithelial organoids model, a recent study demonstrated that butyrate could regulate genes essential for SARS-CoV-2 infection [6] . It also upregulated genes in TLR pathway to increase anti-viral ability of the host [6] . In addition, butyrate can increase the functionalities of gut barrier to prevent translocations of gut pathobionts and lipopolysaccharides into circulation and thus reduce systemic inflammation.

There is a feed-forward effect in the formation of the cytokine storm in COVID-19. In the late stages, anti-inflammatory therapy may not be sufficient to overcome accumulated high levels of cytokines as well as already produced tissue damage and vascular thrombosis. Other studies have also shown that TCZ was effective in the early stages of infection when no mechanical respiratory support was required [7] ; but not effective when enrolled patients needed mechanical ventilation [8] . An early application of anti-inflammatory therapy which could combine anti-IL-6 therapy and commensal bacterial metabolites such as butyrate could greatly reduce the mortality rate of COVID-19.

Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort

IL-6 and CD8+ T cell counts combined are an early predictor of inhospital mortality of patients with COVID-19

Bacterial butyrate prevents atherosclerosis

The Role of butyrate in attenuating pathobiont-induced hyperinflammation

Butyrate regulates COVID-19-relevant genes in gut epithelial organoids from normotensive rats

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial